Study Details

Back to Search Results

A study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT02952092

Astellas Study ID

The unique identification code given by the study sponsor.

1517-CL-0307

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Dialysis in Kidney Disease with Anemia

Phase

These clinical trials are done to confirm that an experimental treatment helps participants who have a specific condition. These clinical trials often compare the experimental treatment to another treatment or, if appropriate, a placebo.

Phase 3

Age

20 years - N/A

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Nov 2016 - Mar 2018

Masking

Double (Participant, Investigator)

Enrollment number

303

A phase 3, multi-center, randomized, 2-arm parallel, double-blind, active-comparator (darbepoetin alfa) conversion study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site JP00035

Saitama, Japan

Site JP00011

Gunma, Japan

Site JP00012

Nagano, Japan

Site JP00004

Ehime, Japan

Site JP00048

Hokkaido, Japan

Site JP00058

Ibaraki, Japan

Site JP00029

Kumamoto, Japan

Site JP00002

Nagano, Japan

Site JP00014

Fukuoka, Japan

Site JP00003

Hokkaido, Japan

Site JP00045

Ibaraki, Japan

Site JP00034

Niigata, Japan

Site JP00047

Ibaraki, Japan

Site JP00016

Saitama, Japan

Site JP00026

Gunma, Japan

Site JP00039

Toyama, Japan

Site JP00040

Aichi, Japan

Site JP00008

Aichi, Japan

Site JP00021

Toyama, Japan

Site JP00050

Gifu, Japan

Site JP00013

Nagasaki, Japan

Site JP00036

Okayama, Japan

Site JP00043

Kagoshima, Japan

Site JP00015

Osaka, Japan

Site JP00051

Nagano, Japan

Site JP00001

Niigata, Japan

Site JP00059

Fukui, Japan

Site JP00030

Gifu, Japan

Site JP00038

Hokkaido, Japan

Site JP00020

Aichi, Japan

Site JP00010

Fukushima, Japan

Site JP00037

Gunma, Japan

Site JP00033

Aichi, Japan

Site JP00005

Kanagawa, Japan

Site JP00007

Osaka, Japan

Site JP00024

Yamagata, Japan

Site JP00044

Tokushima, Japan

Site JP00056

Fukushima, Japan

Site JP00018

Aichi, Japan

Site JP00057

Fukushima, Japan

Site JP00041

Ibaraki, Japan

Site JP00046

Ibaraki, Japan

Site JP00049

Fukuoka, Japan

Site JP00006

Kyoto, Japan

Site JP00028

Kumamoto, Japan

Site JP00055

Ehime, Japan

Site JP00032

Aichi, Japan

Site JP00031

Hokkaido, Japan

Site JP00042

Ibaraki, Japan

Site JP00052

Tokyo, Japan

Site JP00027

Nagano, Japan

Site JP00025

Yamaguchi, Japan

Site JP00009

Fukui, Japan

Site JP00053

Tokyo, Japan

Site JP00054

Ibaraki, Japan

Site JP00017

Ibaraki, Japan

Site JP00022

Toyama, Japan

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo